STERIS plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $STE in the last 7 days.
No SEC Form 4 filings for $STE in the last 30 days.
See all $STE insider activity →UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.
Varonis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.
STERIS plc (STE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01. Entry into a Material Definitive Agreement. On October 11, 2026, STERIS Corporation (“Purchaser”), a wholly owned subsidiary of STERIS plc (“STERIS” or the “Company”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Craig E. Kaforey, individu
Recent STE coverage spans earnings, financial news and mergers & acquisitions.
Acquisition adds surgical product line and revenue.
Debt‑financed acquisition could be neutral to slightly positive.
The deal adds a specialty surgical business but requires $2 billion of new debt, creating near‑term earnings pressure.
No new data; repeats prior earnings release.
The acquisition adds surgical consumables to Steris' portfolio and will be financed primarily with debt, increasing leverage.
AlphAI scores every news story that mentions STE with an AI model for sentiment and relevance, and aggregates insider trades from STERIS plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.
3 min readVaronis Systems (VRNS) rose 2.5% after Proofpoint agreed to acquire it for ~$6.3B. International Paper (IP) gained 7.4% on reports of potential bids for its European packaging business. CCC (CCC) will be acquired for ~$6.1B, Galderma (GALDY) will buy ZO Skin Health for $1.5B, and Bumble (BMBL) surged 57% on a $1.3B acquisition deal. IonQ (IONQ) is acquiring Elisity for up to $1.3B, and STERIS (STE) will buy Xodus Medical for $2.1B.
2 min readSTERIS plc (STE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. ITEM 1.01. Entry into a Material Definitive Agreement. On October 11, 2026, STERIS Corporation (“Purchaser”), a wholly owned subsidiary of STERIS plc (“STERIS” or the “Company”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Craig E. Kaforey, individu
1 min readSolventum (NYSE:SOLV) reported Q2 revenue of $2.21B, up 2.2% YoY, beating estimates. STERIS (NYSE:STE) reported $1.49B, up 7.3% YoY, in line with expectations. BD (NYSE:BDX) reported $4.98B, up 5.4% YoY, beating estimates. CONMED (NYSE:CNMD) reported $343.5M, flat YoY, beating estimates. Stocks reacted accordingly.
2 min readSTERIS plc (NYSE:STE) agreed to acquire Xodus Medical, a Pennsylvania-based surgical products company, for $2.1 billion. The deal includes potential earnout of $150 million and is expected to close by December 31, 2026. Xodus Medical reported projected 2026 revenue of $245 million and adjusted EBIT of $135 million.
2 min readBaxter (BAX) reported Q2 revenue of $2.96B, up 5.3% YoY, beating estimates. LeMaitre (LMAT) reported $70.38M, up 9.6% YoY, missing estimates. STERIS (STE) reported $1.49B, up 7.3% YoY, in line with estimates. Lantheus (LNTH) reported $388.2M, up 2.7% YoY, beating estimates. Stocks are down since reporting.
2 min readSTERIS (STE) has outperformed Abbott Laboratories (ABT) year-to-date and over the past 52 weeks. Analysts give STE a 'Moderate Buy' rating with a mean price target of $263.75, implying 25.4% upside.
1 min readIndustrial SalesLeads tracked 14 chemical and industrial manufacturing projects in August, with 8 focused on chemical manufacturing. The largest project is a $600M sterilization campus in North Carolina. The American Chemistry Council reported high capital spending and record production levels despite rising costs. Projects include investments by Aternium Inc., Steris, Mitsubishi Chemical Advanced Materials, Columbus Chemical Industries, and CF Industries.
2 min readSTERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.
2 min readSohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.
1 min read
%252FSteris%252520Corporation%252520logo%252520is%252520displayed%252520on%252520a%252520smartphone%252520screen_By%252520Rafael%252520Henrique.jpeg&w=384&q=75)